March 1st, 2021
View Archives Issues
In this cross-sectional descriptive study, women using the Ovia pregnancy app expressed receiving adequately safe maternal care during the COVID-19 pandemic, but voiced concerns related to obtaining infant supplies and prenatal education.
This consensus document was developed as a reference for physicians caring for and advising women in pregnancy following prior surgical treatment for pelvic floor disorders.
In this registry-based screening study of women in Catalonia, Spain, a negative human papillomavirus (HPV) and cytology co-test at baseline was associated with a cumulative incidence of cervical precancer of 0.4% at five years and 1.3% at nine years, compared to 27% among women with abnormal HPV testing at baseline.
In this double-blind, randomized clinical trial, 406 pregnant women were randomized to dydrogesterone or placebo. There were no statistically significant differences in the primary outcome (miscarriage before 20 weeks of gestation; relative risk, 0.897; 95% confidence interval, 0.548-1.467; P = 0.772), which occurred in 12.8% and 14.3% in the dydrogesterone and placebo arms, respectively. The use of dydrogesterone in women with threatened miscarriage for the prevention of early pregnancy loss in the first trimester failed to decrease the miscarriage rate or increase the live birth rate.